Attached files
file | filename |
---|---|
EX-32.2 - SECTION 906 CFO CERT - Arbutus Biopharma Corp | ex32_2.htm |
EX-31.2 - SECTION 302 CFO CERT - Arbutus Biopharma Corp | ex31_2.htm |
EX-31.1 - SECTION 302 CEO CERT - Arbutus Biopharma Corp | ex31_1.htm |
EX-10.1 - LEASE AGREEMENT DATED AUGUST 9, 2016 - Arbutus Biopharma Corp | ex10_1.htm |
10-Q/A - Arbutus Biopharma Corp | arbutus10qa_122016.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1.
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
2.
|
The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.
|
Date: December 21, 2016
|
/s/ Mark Murray
|
|
Name: Mark Murray
|
|
Title: President and Chief Executive Officer
|